A Cost-Effectiveness Analysis of Gefitinib as the First Line Treatment in Patients With Positive Egfr Mutation In Metastatic or Locally Advanced non-Small Cell

Small Cell ◽

Line Treatment ◽

First Line ◽

Effectiveness Analysis ◽

Cost-effectiveness analysis of osimertinib for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small cell lung cancer in Singapore

Journal of Medical Economics ◽

10.1080/13696998.2020.1819822 ◽

2020 ◽

Vol 23 (11) ◽

pp. 1330-1339

Author(s):

Mohamed Ismail Abdul Aziz ◽

Wayne Yong Xiang Foo ◽

Chee Keong Toh ◽

Wan-Teck Lim ◽

Kwong Ng

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Egfr Mutation ◽

Locally Advanced ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Effectiveness Analysis ◽

Cost effectiveness analysis of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small-cell lung cancer from the Singapore healthcare payer’s perspective

BMC Cancer ◽

10.1186/s12885-018-4223-y ◽

2018 ◽

Vol 18 (1) ◽

Cited By ~ 7

Author(s):

Ping-Tee Tan ◽

Mohamed Ismail Abdul Aziz ◽

Fiona Pearce ◽

Wan-Teck Lim ◽

David Bin-Chia Wu ◽

...

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Egfr Mutation ◽

Locally Advanced ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Effectiveness Analysis ◽

In response to She et al., “Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greater”

Lung Cancer ◽

10.1016/j.lungcan.2020.06.014 ◽

2020 ◽

Vol 146 ◽

pp. 385-386

Author(s):

Min Huang ◽

Ralph P. Insinga ◽

Thomas Burke ◽

Ying Zhang ◽

Gilberto de Lima Lopes

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Locally Advanced ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Effectiveness Analysis ◽

Cost-Effectiveness Analysis of Afatinib versus Gefitinib for First-Line Treatment of Advanced EGFR -Mutated Advanced Non–Small Cell Lung Cancers

Journal of Thoracic Oncology ◽

10.1016/j.jtho.2017.07.013 ◽

2017 ◽

Vol 12 (10) ◽

pp. 1496-1502 ◽

Cited By ~ 18

Author(s):

Christos Chouaid ◽

Laura Luciani ◽

Katell LeLay ◽

Pascal Do ◽

Jaafar Bennouna ◽

...

Keyword(s):

Cost Effectiveness ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Lung Cancers ◽

Effectiveness Analysis ◽

Egfr Mutated ◽

Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greater

Lung Cancer ◽

10.1016/j.lungcan.2019.10.017 ◽

2019 ◽

Vol 138 ◽

pp. 88-94 ◽

Cited By ~ 10

Author(s):

Longjiang She ◽

Huabin Hu ◽

Mengting Liao ◽

Xuefeng Xia ◽

Yin Shi ◽

...

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Locally Advanced ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Effectiveness Analysis ◽

Cost-effectiveness of osimertinib versus standard EGFR-TKI as first-line treatment for locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer in Australia

Expert Review of Pharmacoeconomics & Outcomes Research ◽

10.1080/14737167.2021.1847648 ◽

2020 ◽

pp. 1-9

Author(s):

Terence Khoo ◽

Lan Gao

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Egfr Mutation ◽

Locally Advanced ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Egfr Tki ◽

Cost-Effectiveness Analysis of Afatinib, Erlotinib, and Gefitinib as First-Line Treatments for EGFR Mutation-Positive Non-Small-Cell Lung Cancer in Ontario, Canada

PharmacoEconomics ◽

10.1007/s40273-021-01022-9 ◽

2021 ◽

Author(s):

Yong-Jin Kim ◽

Mark Oremus ◽

Helen H. Chen ◽

Thomas McFarlane ◽

Danielle Fearon ◽

...

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Egfr Mutation ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Effectiveness Analysis

Cost-Effectiveness Analysis Of Panitumumab + Folfox Compared To Cetuximab + Folfiri As First-Line Treatment For Patients With Wild-Type (Wt) Ras (Exons 2, 3, And 4 Of Kras And Nras) Metastatic Colorectal Cancer (Mcrc) In Colombia

Value in Health ◽

10.1016/j.jval.2015.09.1188 ◽

2015 ◽

Vol 18 (7) ◽

pp. A460 ◽

Cited By ~ 2

Author(s):

J Vargas-Valencia ◽

J Garcia Perlaza

Keyword(s):

Colorectal Cancer ◽

Cost Effectiveness ◽

Metastatic Colorectal Cancer ◽

Line Treatment ◽

Wild Type ◽

First Line ◽

Effectiveness Analysis ◽

Cost-effectiveness analysis in the Spanish setting of the PEAK trial of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer

Journal of Medical Economics ◽

10.1080/13696998.2017.1285780 ◽

2017 ◽

Vol 20 (6) ◽

pp. 574-584 ◽

Cited By ~ 3

Author(s):

Fernando Rivera ◽

Manuel Valladares ◽

Salvador Gea ◽

Noemí López-Martínez

Keyword(s):

Colorectal Cancer ◽

Cost Effectiveness ◽

Metastatic Colorectal Cancer ◽

Line Treatment ◽

Wild Type ◽

First Line ◽

Effectiveness Analysis ◽

Cost-Effectiveness Analysis Comparing FOLFIRINOX and Nab-Paclitaxel (Abaraxane) Plus Gemcitabine For First-Line Treatment Of Patients with Metastatic Pancreatic Cancer from the US Societal Perspective

Value in Health ◽

10.1016/j.jval.2016.03.1607 ◽

2016 ◽

Vol 19 (3) ◽

pp. A153

Author(s):

W Cheng ◽

JW Hay

Keyword(s):

Pancreatic Cancer ◽

Cost Effectiveness ◽

Societal Perspective ◽

Metastatic Pancreatic Cancer ◽

Line Treatment ◽

First Line ◽

Effectiveness Analysis ◽

The Us ◽